Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

Analyst Ratings

Consensus Ratings for Aclaris Therapeutics (NASDAQ:ACRS) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.50 (40.74% upside)

Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016GuggenheimInitiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2016Jefferies GroupReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Lower Price TargetBuy$34.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015William BlairInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/11/2016        
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.54)($0.54)($0.54)
Q3 20161($0.57)($0.57)($0.57)
Q4 20161($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aclaris Therapeutics (NASDAQ:ACRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aclaris Therapeutics (NASDAQ:ACRS)
DateHeadline
07/26/16 02:19 PMCommerceHub (Nasdaq: CHUBA, CHUBK) to Ring The Nasdaq Stock Market Opening Bell
07/25/16 07:00 AMAclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis (SK); Provides Update on Clinical Programs - [GlobeNewswire] - MALVERN, Pa., July 25, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced the completion of patient enrollment in its two Phase 3 pivotal clinical trials ...
07/05/16 07:39 AMAclaris Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [GlobeNewswire] - MALVERN, Pa., July 05, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at Cantor ...
06/29/16 03:08 PMACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 05:22 AMCoverage initiated on Aclaris Therapeutics by Guggenheim -
06/02/16 03:18 PMACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit -
05/31/16 07:48 AMAclaris Therapeutics to Present at Upcoming Investor Conferences in June - [GlobeNewswire] - MALVERN, Pa., May 31, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President& Chief Executive Officer, will present at three ...
05/24/16 10:55 AMBiotech Movers and Shakers: Aclaris Therapeutics Inc (NASDAQ:ACRS) and XenoPort, Inc. (NASDAQ:XNPT) - Market Exclusive - Market ExclusiveBiotech Movers and Shakers: Aclaris Therapeutics Inc (NASDAQ:ACRS) and XenoPort, Inc. (NASDAQ:XNPT)Market ExclusiveA number of companies are up and down on a host of release types, and with earnings season in full swing, there's plenty to drive volatility in the sector. With this in mind, here are two of the week's biggest movers – Aclaris Therapeutics Inc (NASDAQ ...Analyst Coverage: Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Risers & FallersCould Aclaris Therapeutics Inc Gain Strenght? The Stock Reaches 52-Week LowThe Postall 3 news articles »
05/21/16 11:35 AMRevenue Update on Aclaris Therapeutics Inc(NASDAQ:ACRS) - Trade Calls - Revenue Update on Aclaris Therapeutics Inc(NASDAQ:ACRS)Trade CallsAclaris Therapeutics Inc(NASDAQ:ACRS) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 11, 2016. Earnings per share were $-0.65. Analysts had estimated an EPS of $-0.48. In a different note, On ...Were Analysts Bearish Aclaris Therapeutics Inc (NASDAQ:ACRS) This Week?Wall Street Hints and Newsall 2 news articles »
05/20/16 11:28 AMWere Analysts Bearish Aclaris Therapeutics Inc (NASDAQ:ACRS) This Week? - Wall Street Hints and News - Were Analysts Bearish Aclaris Therapeutics Inc (NASDAQ:ACRS) This Week?Wall Street Hints and NewsOut of 3 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Aclaris Therapeutics has been the topic of 4 analyst reports since November 2, 2015 according to StockzIntelligence ...and more »
05/16/16 10:51 AMHot Stocks – ACIA, HTGM, LINK, NVDA, AIQ, ACRS, CXRX - The company is -14.81 pct year-to-date, and -62.52 pct during the past four quarters. Aclaris Therapeutics Inc (ACRS) traded at $19.42 + 2.49 (14.70 pct) on 105,480 total stock volume. The company is -27.92 pct year-to-date, and — during the past four ...
05/16/16 09:54 AMWhy Pfizer's Anacor Purchase is Good News for Dermira, Aclaris -
05/12/16 10:36 AMThe Week's Big Biotech Losers: Aclaris Therapeutics Inc (NASDAQ:ACRS) and Inotek Pharmaceuticals Corp (NASDAQ ... - Market Exclusive - Market ExclusiveThe Week's Big Biotech Losers: Aclaris Therapeutics Inc (NASDAQ:ACRS) and Inotek Pharmaceuticals Corp (NASDAQ ...Market ExclusiveIt's been another busy week in biotech, with earnings season still playing a large part in the majority of the volume driven volatility in the space. Here's a look at two of the week's biggest movers, and a consideration of what drove the action, in ...Small Cap Losers: Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE), Celldex Therapeutics, Inc. (NASDAQ:CLDX ...KC Registerall 4 news articles »
05/11/16 06:25 PMEdited Transcript of ACRS earnings conference call or presentation 11-May-16 12:30pm GMT -
05/11/16 07:30 AMAclaris Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
05/11/16 06:32 AMACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
05/11/16 06:07 AMAclaris reports 1Q loss -
05/11/16 06:07 AMQ1 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open -
05/11/16 06:00 AMAclaris Therapeutics Reports First Quarter 2016 Financial Results - [GlobeNewswire] - MALVERN, Pa., May 11, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2016 and provided an ...
05/10/16 10:56 AMInnovus Pharma (INNV): Targeting $3+ Billion Markets with 13 Commercial Products - JNP), Aclaris Therapeutics Inc. (NASDAQ: ACRS), or Teligent Inc. (NASDAQ: TLGT), may want to take a closer look at the stock. For more information, visit the company’s website at www.innovuspharma.com.
05/10/16 10:56 AMDrug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More - Let’s take a peek at a few drug stocks that will report quarterly results on May 11. Aclaris Therapeutics, Inc. ACRS, a clinical-stage specialty pharmaceutical company, is scheduled to report first-quarter results on May 11. With its focus on dermatology ...
05/05/16 10:59 AMAclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 4.01% Their Shorts - B.O.D.Y Confidential - Aclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 4.01% Their ShortsB.O.D.Y ConfidentialThe short interest to Aclaris Therapeutics Incorporated's float is 4.64%. The stock is down 4.51% or $0.93 after the news, hitting $19.7 per share. About 19,611 shares traded hands. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 6.00% since April 4, ...and more »
05/05/16 07:25 AMAclaris Therapeutics, Inc. Appoints Kevin Scott as Vice President of Sales - [GlobeNewswire] - MALVERN, Pa., May 05, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced that it has appointed Kevin Scott, an experienced sales executive within the ...
05/03/16 10:30 AMAclaris Therapeutics to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference - Nasdaq - Aclaris Therapeutics to Present at the Bank of America Merrill Lynch 2016 Healthcare ConferenceNasdaqA live audio webcast of the Aclaris presentation can be accessed by visiting the "Investors" section of the company's website at www.aclaristx.com. A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the ...and more »
05/02/16 03:05 PMAclaris Therapeutics to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference - [GlobeNewswire] - MALVERN, Pa., May 02, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President& Chief Executive Officer, will present at the ...
04/27/16 11:26 AMAfter Last Week What Do Analysts Think Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Share Trading News - After Last Week What Do Analysts Think Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Share Trading NewsThey now have a USD 20 price target on the stock. The share price of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) was up +0.10% during the last trading session, with a day high of 20.00. 23074 shares were traded on Aclaris Therapeutics, Inc.'s last session.Aclaris Therapeutics to Announce First Quarter 2016 Financial Results on May 11, 2016GlobeNewswire (press release)all 2 news articles »
04/26/16 03:05 PMAclaris Therapeutics to Announce First Quarter 2016 Financial Results on May 11, 2016 - [GlobeNewswire] - MALVERN, Pa., April 26, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, will release its first quarter financial results before the market opens on Wednesday, May ...
04/25/16 10:59 AMAclaris Therapeutics Incorporated (NASDAQ:ACRS) Shorted Shares Increased 1.82% After Market Selling - The stock decreased 0.15% or $0.03 on April 22, hitting $19.66. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 6.00% since March 26, 2016 and is uptrending. It has outperformed by 0.91% the S&P500. Aclaris Therapeutics, Inc. is a United States clinical ...
04/22/16 11:08 AMAclaris Therapeutics, Inc. (NASDAQ:ACRS) Updated Broker Ratings - Risers & Fallers - Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...
04/15/16 10:46 AMAclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 1.82% Their Shorts - Stock Caller - Aclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 1.82% Their ShortsStock CallerThe short interest to Aclaris Therapeutics Incorporated's float is 4.46%. The stock increased 0.50% or $0.1 on April 14, hitting $20.1. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 6.00% since March 16, 2016 and is uptrending. It has underperformed ...and more »
04/14/16 10:35 AMLatest Analyst Ratings For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Share Trading News - Latest Analyst Ratings For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). The most recent broker reports which have been released note that 3 ...
04/09/16 10:00 AMRecently Changed Price Targets On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Risers & Fallers - Recently Changed Price Targets On Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). According to the latest broker reports 3 analysts have a rating of “buy”, 0 analysts “outperform”, 0 analysts “hold”, 0 ...
04/08/16 01:51 PMIf Valeant Sells Bausch & Lomb, Will Allergan Be a Bidder? -
04/06/16 10:18 AMWhat Next for Aclaris Therapeutics Inc Stock After Today's Huge Decline? - Stock Caller - What Next for Aclaris Therapeutics Inc Stock After Today's Huge Decline?Stock CallerThe stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) is a huge mover today! The stock decreased 3.95% or $0.81 during the last trading session, hitting $19.69. About 56,027 shares traded hands or 49.85% up from the average. Aclaris Therapeutics Inc ...and more »
04/05/16 09:52 AMAnalyst Coverage: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Risers & Fallers - Seeking AlphaAnalyst Coverage: Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). The latest broker reports which are currently outstanding on Tuesday 5th of April state 3 analysts have a rating of “strong buy”, ...Is This A Joke: Aclaris Therapeutics' Lead Proprietary Drug Is H2O2?Seeking Alphaall 2 news articles »
04/01/16 10:01 AMRevenue Update on Aclaris Therapeutics Inc(NASDAQ:ACRS) - Street Edition - Revenue Update on Aclaris Therapeutics Inc(NASDAQ:ACRS)Street EditionIn a different note, On Mar 16, 2016, Citigroup said it Maintains its rating on Aclaris Therapeutics Inc. In the research note, the firm Lowers the price-target to $34.00 per share. The shares have been rated 'Buy' by the firm. Several Insider ...and more »
03/31/16 09:40 AMAnalyst Review: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Risers & Fallers - Analyst Review: Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). According to the latest broker reports outstanding on Thursday 31st of March, 3 analysts have a rating of “strong buy”, ...
03/30/16 03:34 PMACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition -
03/29/16 12:04 PMACLARIS THERAPEUTICS, INC. Financials -
03/29/16 09:51 AMHair-raising deal: Malvern biopharm firm acquires company targeting male pattern baldness - Aclaris Therapeutics Inc., in welcome news for the estimated two-thirds of American ... Neal Walker, the president and CEO of Aclaris (NASDAQ: ACRS) in Malvern, Pa., said the Vixen deal, along with the one last year, will allow Alcaris to broaden its ...
03/29/16 09:51 AMAclaris Therapeutics (ACRS) to Acquire Vixen Pharma and Rights to Intellectual Property for Potential Treatment for Hair Loss - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical stage specialty pharmaceutical company, today announced that it has entered into an agreement with the stockholders ...
03/28/16 03:05 PMAclaris Therapeutics Acquires Worldwide Rights to Compounds and Key Intellectual Property for Potential Treatment for Hair Loss - [GlobeNewswire] - MALVERN, Pa., March 28, 2016-- Aclaris Therapeutics, Inc., a clinical stage specialty pharmaceutical company, today announced that it has entered into an agreement with the stockholders of Vixen Pharmaceuticals, ...
03/24/16 02:00 PMEdited Transcript of ACRS earnings conference call or presentation 23-Mar-16 8:30pm GMT -
03/24/16 10:32 AMLOUISVILLE, Ky — The Mets’ misery made for one of Mark Turgeon’s best nights - Dazu schreibt newratings.com: NEW YORK CITY - Aclaris Therapeutics Inc (ACRS) is one stock to watch out for this year as the company has a couple of catalysts coming its way The company expects to report phase III results for A-101 Topical Solution for the ...
03/24/16 10:32 AMACLS THER : Aclaris reports 4Q loss - MALVERN, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Wednesday reported a loss of $4.7 million in its fourth quarter. On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 28 cents. For the year, the company reported profit ...
03/24/16 12:26 AMOdyssey Hits The Mark, SPHS Awaits Data In Q2, TEVA Breathes Easy - (RTTNews.com) - Aclaris Therapeutics Inc. ( ACRS) is one stock to watch out for this year as the company has a couple of catalysts coming its way. The company expects to report phase III results for A-101 Topical Solution for the treatment of seborrheic ...
03/23/16 03:30 PMAclaris Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today -
03/23/16 03:09 PMAclaris reports 4Q loss -
03/23/16 03:01 PMAclaris Therapeutics Reports Fourth Quarter and Full Year 2015 Operating and Financial Results - [GlobeNewswire] - MALVERN, Pa., March 23, 2016-- Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2015 and ...
03/23/16 06:07 AMQ4 2015 Aclaris Therapeutics Inc Earnings Release - After Market Close -

Social

About Aclaris Therapeutics

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company's drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts. In addition, the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company's products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company's A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company's A-201 and A-301 products are in pre- clinical stage.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRS
  • CUSIP:
Key Metrics:
  • Previous Close: $19.72
  • 50 Day Moving Average: $19.74
  • 200 Day Moving Average: $19.35
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $412.41M
  • Current Year EPS Consensus Estimate: $-2.45 EPS
  • Next Year EPS Consensus Estimate: $-2.36 EPS
Additional Links:
Aclaris Therapeutics (NASDAQ:ACRS) Chart for Tuesday, July, 26, 2016